Piper Sandler Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) and raised the price target from $48 to $51.
October 11, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Edgewise Therapeutics and increased the price target from $48 to $51, indicating positive analyst sentiment.
The increase in price target from $48 to $51 by Piper Sandler suggests a positive outlook for Edgewise Therapeutics, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100